Drug Resistant Cancers
What is it?
The development of drug resistance is perhaps the most challenging problem we face in the fight against cancer. A significant number of patients with drug-resistant cancer experience early treatment failure (they don’t respond), partial response (they respond but their disease does not go away), or relapse (their disease disappears but recurs several years after treatment is stopped).Approximately 500,000 people in the U.S. die each year from cancer which is resistant to chemotherapy. We focus on two different types of cancers where resistance to doxorubicin (DOXIL) is problematic, Non-Hodgkin's lymphoma and ovarian cancers.
Ovarian cancer is the ninth most common form of cancer in women, but the fifth highest cause of cancer death in women. Symptoms of ovarian cancer are vague and can be easily misdiagnosed. When coupled with resistance to current treatments, it's not surprising that ovarian cancer is certainly a daunting disease.
Non- Hodgkin Lymphone (NHL) is not a single disease, but a group of closely related cancers which all have unique identifiers and treatments.NHL is the most common form of lymphatic cancer, accounting for over 60% of all cases of lymphatic cancer.
We have created a novel platform to develop drugs that combat drug-resistant cancers. Using this platform we hope to develop a drug that will improve cure rates by reducing drug-resistance of cancer cells to current combinatorial drug therapies and lowering the toxicity of current treatments.
RTI Compounds interfere with the cellular xenobiotic response to drug therapy by inhibiting Nrf-2 activity in the cell.